Biocon posts strong Q2 FY26 results, announces strategic financial moves

Biocon Limited reported a significant financial uplift for Q2 FY26, with consolidated operating revenue reaching Rs 4,296 crore, a 20% year-on-year increase. EBITDA grew 29% to Rs 928 crore, while PBT (before exceptional items) surged 153% to Rs 183 crore. The biosimilars segment led this growth with Rs 2,721 crore (up 25% YoY), followed by generics at Rs 774 crore (up 24% YoY), and CRDMO contributing Rs 911 crore (up 2% YoY).

The company's board approved the early full redemption of 50,000 unlisted non-convertible debentures, totaling Rs 500 crore, issued on May 19, 2023. Additionally, Biocon will acquire 1,06,86,044 compulsorily convertible debentures of Biocon Biologics Limited, an unlisted material subsidiary, from ESOF III Investment Fund and EAAA India Alternatives Limited for Rs 10/- each, aggregating to Rs 300 crore. This acquisition is expected to increase Biocon’s holding in BBL by approximately 65 basis points.

Furthermore, Biocon plans to issue commercial papers up to Rs 550 crore in one or more tranches on a private placement basis.